Tempest Therapeutics (NASDAQ:TPST) Posts Quarterly Earnings Results

Tempest Therapeutics (NASDAQ:TPST) announced its quarterly earnings data on Monday. The company reported ($0.62) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.62), FiscalAI reports.

Tempest Therapeutics Price Performance

Shares of Tempest Therapeutics stock opened at $1.73 on Monday. The business has a fifty day simple moving average of $2.37 and a two-hundred day simple moving average of $5.27. Tempest Therapeutics has a 1 year low of $1.56 and a 1 year high of $12.23. The company has a market capitalization of $8.52 million, a price-to-earnings ratio of -0.17 and a beta of -2.42.

Insider Activity at Tempest Therapeutics

In related news, CEO Matthew Angel acquired 231,482 shares of the company’s stock in a transaction dated Tuesday, March 24th. The shares were bought at an average cost of $2.16 per share, with a total value of $500,001.12. Following the completion of the transaction, the chief executive officer directly owned 231,482 shares of the company’s stock, valued at $500,001.12. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 6.28% of the stock is currently owned by corporate insiders.

Institutional Trading of Tempest Therapeutics

A hedge fund recently raised its stake in Tempest Therapeutics stock. Vanguard Group Inc. boosted its stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) by 20.8% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 162,560 shares of the company’s stock after buying an additional 27,952 shares during the period. Vanguard Group Inc. owned approximately 3.66% of Tempest Therapeutics worth $1,671,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 22.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempest Therapeutics in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $12.50.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.